Article ; Online: Antiplatelet Agent Use After Stroke due to Intracerebral Hemorrhage.
2023 Volume 54, Issue 12, Page(s) 3173–3181
Abstract: This focused update about antiplatelet agents to reduce the high risk of major adverse cardiovascular events after stroke due to spontaneous (nontraumatic) intracerebral hemorrhage (ICH) complements earlier updates about blood pressure-lowering, lipid- ... ...
Abstract | This focused update about antiplatelet agents to reduce the high risk of major adverse cardiovascular events after stroke due to spontaneous (nontraumatic) intracerebral hemorrhage (ICH) complements earlier updates about blood pressure-lowering, lipid-lowering, and oral anticoagulation or left atrial appendage occlusion for atrial fibrillation after ICH. When used for secondary prevention in people without ICH, antiplatelet agents reduce the risk of major adverse cardiovascular event (rate ratio, 0.81 [95% CI, 0.75-0.87]) and might increase the risk of ICH (rate ratio, 1.67 [95% CI, 0.97-2.90]). Before 2019, guidance for clinical decisions about antiplatelet agent use after ICH has focused on estimating patients' predicted absolute risks and severities of ischemic and hemorrhagic major adverse cardiovascular event and applying the known effects of these drugs in people without ICH to estimate whether individual ICH survivors in clinical practice might be helped or harmed by antiplatelet agents. In 2019, the main results of the RESTART (Restart or Stop Antithrombotics Randomized Trial) randomized controlled trial including 537 survivors of ICH associated with antithrombotic drug use showed, counterintuitively, that antiplatelet agents might not increase the risk of recurrent ICH compared to antiplatelet agent avoidance over 2 years of follow-up (12/268 [4%] versus 23/268 [9%]; adjusted hazard ratio, 0.51 [95% CI, 0.25-1.03]; |
---|---|
MeSH term(s) | Humans ; Platelet Aggregation Inhibitors/adverse effects ; Treatment Outcome ; Cerebral Hemorrhage/complications ; Stroke/drug therapy ; Stroke/prevention & control ; Stroke/complications ; Fibrinolytic Agents/therapeutic use ; Anticoagulants/therapeutic use |
Chemical Substances | Platelet Aggregation Inhibitors ; Fibrinolytic Agents ; Anticoagulants |
Language | English |
Publishing date | 2023-11-02 |
Publishing country | United States |
Document type | Journal Article ; Review |
ZDB-ID | 80381-9 |
ISSN | 1524-4628 ; 0039-2499 ; 0749-7954 |
ISSN (online) | 1524-4628 |
ISSN | 0039-2499 ; 0749-7954 |
DOI | 10.1161/STROKEAHA.123.036886 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 448: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.